Prostate cancer decisions — 2025

The Board remands the claim for service connection of prostate cancer to schedule a new VA examination due to an inadequate previous opinion and additional evidence provided by the Veteran.

The Board remands all issues on appeal for additional development, including verification of potential exposure to herbicide agents and other chemicals, as well as obtaining any relevant treatment records.

The Board remands the claim for a new VA examination to address an inadequate May 2022 VA medical examination and to consider private medical records showing a history of malignant neoplasm of the prostate.

The Board remands the claim for service connection for prostate cancer due to pre-decisional duty to assist errors, including inadequate medical opinions and missing records.

The Board denied a rating in excess of 70 percent for PTSD, granted a 20 percent rating for prostate cancer, and denied ratings in excess of 10 percent for bilateral hearing loss. The Board also denied service connection for generalized anxiety disorder, other specified depressive disorder, gout, and tremors.

The Board denied service connection for prostate cancer, finding no evidence linking the condition to the Veteran's active service or exposure at Camp Lejeune.

The Board denied service connection for a heart condition due to the lack of evidence showing a current diagnosis or residuals, and remanded claims for hypertension and prostate cancer for further development.

The Board remands the claims for service connection for hypertension, prostate cancer, bladder cancer, and bilateral hearing loss due to a pre-decisional duty to assist error.

The Board remands the claims for service connection for type two diabetes mellitus, heart condition, and prostate cancer to obtain a medical examination addressing the nature and etiology of the Veteran's claimed conditions.

The Board remands the issue of entitlement to service connection for prostate cancer, to include as due to Agent Orange exposure, for further development and readjudication.

The Board denied service connection for left shoulder condition, bilateral peripheral neuropathy, diabetes mellitus type II, prostate cancer, and hypertension as the evidence did not support a finding that any of these conditions were related to the Veteran's active duty service.

The Board remands the claim for service connection for prostate cancer due to a pre-decisional error in the obtained medical examination and the need to verify any and all periods of service, including active duty, ACDUTRA/ADT or INACDUTRA/IDT.

The Board remands the claims for service connection for prostate cancer, hiatal hernia, and umbilical hernia to correct pre-decisional duty to assist errors.

The Board denied service connection for emphysema, finding that the Veteran's current condition was more likely related to his history of smoking than to his military service. The claims for prostate cancer and hernia were remanded for further examination.

The Board denied the veteran's claims for a compensable rating for bilateral hearing loss, earlier effective dates for prostate cancer and erectile dysfunction, dismissed incontinence, and remanded diabetes and COPD. Prostate cancer was granted with an initial 100% rating from January 6, 2020.

The Board granted service connection for prostate cancer and residuals, including erectile dysfunction and voiding dysfunction, as due to herbicide exposure based on the evidence showing that the Veteran was exposed to herbicide agents while serving at Fort McClellan.

The Board granted service connection for prostate cancer residuals, Parkinson's disease, ischemic heart disease, hypothyroidism, peripheral neuropathy, and testicular disability on a basis other than the PACT Act.

The Board denied service connection for high cholesterol and remanded the claims for prostate cancer, arthritis, diabetes type II, end stage renal disease on dialysis, nerve pain (including diabetic neuropathy), and kidney cancer for further development.

The Board denied the Veteran's claims for increased ratings for bilateral hearing loss and tinnitus, and remanded several service connection claims due to missing service treatment records.

The Board remands the claims for service connection for multiple myeloma, prostate cancer, and chronic kidney disease due to a need for additional development of evidence regarding exposure to toxic substances during service.